Skip to main content

Test tubes filled with liquid

report Life Sciences

Drug discovery (img: motorolka_10/shutterstock)

Drug discovery (img: motorolka_10/shutterstock)


Charity finances Polyphor research

The pharmaceutical company Polyphor has received CHF 2.3 million to advance research work on a particular antibiotic. Polyphor has been very successful in developing medicines against drug-resistant pathogens.

The non-profit Wellcome Trust has awarded Polyphor CHF 2.3 million in research funding. Wellcome is the world’s largest biomedical research funding charity with a strong commitment to antibacterial research and development.

Polyphor has developed a new product class called Outer Membrane Polyphor Targeting Antibiotics (OMPTA), which has shown outstanding efficacy against the most resistant strains of certain pathogens, according to a Polyphor statement. The funding awarded by Wellness will enable the pharmaceutical company from the canton of Basel-Landschaft to now accelerate the development of broad-spectrum, Gram-negative pre-clinical product candidates.

“The resistance of bacteria to antibiotics is a growing and significant global public health issue,” said Polyphor CEO Giacomo Di Nepi. “The support from Wellcome will help us advance our novel broad-spectrum antibiotics even more expeditiously towards the first clinical trial.” He added that the award “exemplifies Polyphor’s strategy of translating innovative research into new medicines that address major unmet needs”.

Share this article

View all news

Sign up to receive our newsletter in your inbox.